References

1. Lemke TL, Williams DA, Roche VF and Zito SW. *Foye's principles of medicinal chemistry*- sixth edition. Philadelphia: Lippincott Williams & Wilkins; 2008.

2. Block JH and Beale JM Jr. *Wilson and Gisvold's Textbook of of Organic Medicinal and Pharmaceutical Chemistry*. Eleventh edition. Philadelphia: Lippincott Williams & Wilkins 2004. p. 919-923.

3. Buyya R, Branson K, Giddy J, Abramson D. The Virtual Laboratory: a toolset to enable distributed molecular modeling for drug design on the World-Wide Grid. *Concurrency and Computation: practice and experience*. 2003; 15:1-25.

4. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg. Med. Chem. (2012).

5. Altintas H, Ates O, Birteksoz S,Otuk G, Uzun M, Satana D. Synthesis of Mannich Bases of Some 2, 5-Disubstituted 4-Thiazolidinones and Evaluation of Their Antimicrobial Activities. *Turk J Chem.* 2005; 29: 425 - 435.

6. Galletti P, Giacomini D. Monocyclic β-lactams: new structures for new biological activities. *Curr Med Chem.* 2011;18(28):4265-83.

7. Global Tuberculosis Report, 2013, WHO: pg1

8. Zhang Y, Yew WW. Mechanisms of drug resistance in *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis*. 2009; 13(11):1320-30.

9. Kaminskyy D, Khyluk D, Vasylenko O, Zaprutko L, Lesyk R. A Facile Synthesis and Anticancer Activity Evaluation of Spiro[Thiazolidinone-Isatin] Conjugates. *Sci Pharm*. **2011;** 79(4): 763–777.

10. Hearn MJ, Cynamon MH, et al. Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid**.** *Eur J Med Chem.* 2009 ; 44(10): 4169–4178.

11. Takyama K, Wang C, Besra GS. Pathway to Synthesis and Processing of Mycolic acis in *Mycobacterium tuberculosis*. *Clinical Microbiology Reviews*.2005; 18(1):81-101.

12. Gurvitz A, Hiltunen JK, Kastaniotis AJ.Function of Heterologous *M.tuberculosis* Inh A, a Type II Fatty acid Synthase Enzyme involved in Extending C Fatty Acids to C-to- C Mycolic acids, during De Novo Lipoic Acid Synthesis in *Saccharomyces cerevisiae*. *Applied Environmental Microbiology*.2008; 74(16):5078-5085.

13. Dewitt DL. Cox-2-Selective Inhibitors: The New Super Aspirins. *MOLECULAR PHARMACOLOGY*.1999; 55:625–631.

15. Schrodinger suite user manual. Ligprep user manual: lp_25 user manual, 1-3 (2011).

16. Winter CA, Risley EA, Nuss GW. Carrageenan-induced edema in hind paws of the rat as an assay for antiinflammatory drugs. *Proc. Soc. Exp. Biol. Med.* 1962; 111: 544 - 55.

17. Inoue T, Tanaka K, Mishima M, Watanabe K. Predictive *in vitro* cardiotoxicity and hepatotoxicity screening system using neonatal rat heart cells and rat hepatocytes. AATEX 14, Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences2007; Special Issue: 457-462.